Nuclear medicine uses radioactive materials known as radiopharmaceuticals to diagnose and treat many disease processes. Acknowledging the risks inherent to radiopharmaceuticals and underscoring the significance of strict adherence to safety protocols is imperative. Regulatory authorities such as the Nuclear Regulatory Commission (NRC) and the International Commission on Radiological Protection (ICRP) have established comprehensive standards governing radiopharmaceutical handling, administration, and disposal.
To ensure compliance with these standards, physicians must attain authorized user (AU) status, which grants the authority to prescribe and oversee procedures involving radiopharmaceuticals. Achieving AU status requires specific qualifications, including board certification in radiology, nuclear medicine, or radiation oncology. Board certification demonstrates completion of postgraduate residency or fellowship programs and competence in dose calculations, radiobiology, decontamination procedures, practical experience in handling radioisotopes, patient release calculations, written directives, and clinical supervision.
This activity aims to consolidate critical safety policies encompassing the proper utilization of protective equipment when handling radiopharmaceuticals, adherence to exposure thresholds for personnel, and adherence to maximum exposure limits for patients and staff. The overarching objective is to reinforce and promote best practices within an evolving medical subspecialty where advanced techniques necessitate optimizing safety protocols to harness nuclear medicine's diagnostic and therapeutic benefits. This activity will focus on NRC regulations; the ICRP and the International Atomic Energy Agency (IAEA) have similar, albeit slightly varied regulations. The dynamic nature of regulatory guidelines for radiopharmaceuticals cannot be understated. Regulations also demonstrate geographic variance; a comprehensive understanding of and adherence to specific local regulations is required.
Copyright © 2024, StatPearls Publishing LLC.